These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

823 related articles for article (PubMed ID: 33393854)

  • 1. SARS-CoV-2 reinfection and implications for vaccine development.
    Nainu F; Abidin RS; Bahar MA; Frediansyah A; Emran TB; Rabaan AA; Dhama K; Harapan H
    Hum Vaccin Immunother; 2020 Dec; 16(12):3061-3073. PubMed ID: 33393854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: The status and perspectives in delivery points of view.
    Chung JY; Thone MN; Kwon YJ
    Adv Drug Deliv Rev; 2021 Mar; 170():1-25. PubMed ID: 33359141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate.
    Patel DR; Field CJ; Septer KM; Sim DG; Jones MJ; Heinly TA; Vanderford TH; McGraw EA; Sutton TC
    J Virol; 2021 Jun; 95(13):e0223220. PubMed ID: 33827954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection.
    Cromer D; Juno JA; Khoury D; Reynaldi A; Wheatley AK; Kent SJ; Davenport MP
    Nat Rev Immunol; 2021 Jun; 21(6):395-404. PubMed ID: 33927374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
    Jalkanen P; Kolehmainen P; Häkkinen HK; Huttunen M; Tähtinen PA; Lundberg R; Maljanen S; Reinholm A; Tauriainen S; Pakkanen SH; Levonen I; Nousiainen A; Miller T; Välimaa H; Ivaska L; Pasternack A; Naves R; Ritvos O; Österlund P; Kuivanen S; Smura T; Hepojoki J; Vapalahti O; Lempainen J; Kakkola L; Kantele A; Julkunen I
    Nat Commun; 2021 Jun; 12(1):3991. PubMed ID: 34183681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19.
    Karthik K; Senthilkumar TMA; Udhayavel S; Raj GD
    Hum Vaccin Immunother; 2020 Dec; 16(12):3055-3060. PubMed ID: 32845733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and prospective computational approaches and challenges for developing COVID-19 vaccines.
    Hwang W; Lei W; Katritsis NM; MacMahon M; Chapman K; Han N
    Adv Drug Deliv Rev; 2021 May; 172():249-274. PubMed ID: 33561453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
    Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
    Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2.
    Mudgal R; Nehul S; Tomar S
    Hum Vaccin Immunother; 2020 Dec; 16(12):2921-2931. PubMed ID: 32931361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fast-spreading COVID variant can elude immune responses.
    Callaway E
    Nature; 2021 Jan; 589(7843):500-501. PubMed ID: 33479534
    [No Abstract]   [Full Text] [Related]  

  • 15. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
    Chakraborty S; Mallajosyula V; Tato CM; Tan GS; Wang TT
    Adv Drug Deliv Rev; 2021 May; 172():314-338. PubMed ID: 33482248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.
    Batty CJ; Heise MT; Bachelder EM; Ainslie KM
    Adv Drug Deliv Rev; 2021 Feb; 169():168-189. PubMed ID: 33316346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Covid-19 reinfections: what is the clinical relevance?].
    Wiersinga WJ; de Bree GJ
    Ned Tijdschr Geneeskd; 2020 Dec; 164():. PubMed ID: 33332056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How bad is Omicron? What scientists know so far.
    Callaway E; Ledford H
    Nature; 2021 Dec; 600(7888):197-199. PubMed ID: 34857948
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
    Adv Drug Deliv Rev; ; . PubMed ID: 33422546
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 42.